CA2412484A1 - G-protein coupled receptors - Google Patents

Info

Publication number

CA2412484A1

CA2412484A1 CA002412484A CA2412484A CA2412484A1 CA 2412484 A1 CA2412484 A1 CA 2412484A1 CA 002412484 A CA002412484 A CA 002412484A CA 2412484 A CA2412484 A CA 2412484A CA 2412484 A1 CA2412484 A1 CA 2412484A1

Authority

CA

Canada

Prior art keywords

polynucleotide

polypeptide

seq

gcrec

antibody

Prior art date

2000-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract description 365
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract description 363
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 305
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 305
• 239000002157 polynucleotide Substances 0.000 claims abstract description 305
• 238000000034 method Methods 0.000 claims abstract description 197
• 230000014509 gene expression Effects 0.000 claims abstract description 140
• 239000005557 antagonist Substances 0.000 claims abstract description 25
• 239000000556 agonist Substances 0.000 claims abstract description 21
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 238
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 222
• 229920001184 polypeptide Polymers 0.000 claims description 215
• 210000004027 cell Anatomy 0.000 claims description 160
• 239000012634 fragment Substances 0.000 claims description 136
• 150000001875 compounds Chemical class 0.000 claims description 117
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 101
• 239000000523 sample Substances 0.000 claims description 94
• 150000007523 nucleic acids Chemical class 0.000 claims description 77
• 238000009396 hybridization Methods 0.000 claims description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
• 239000000203 mixture Substances 0.000 claims description 60
• 238000012360 testing method Methods 0.000 claims description 60
• 230000000694 effects Effects 0.000 claims description 59
• 239000002773 nucleotide Substances 0.000 claims description 57
• 125000003729 nucleotide group Chemical group 0.000 claims description 57
• 102000039446 nucleic acids Human genes 0.000 claims description 41
• 108020004707 nucleic acids Proteins 0.000 claims description 41
• 230000027455 binding Effects 0.000 claims description 38
• 230000000295 complement effect Effects 0.000 claims description 37
• 201000010099 disease Diseases 0.000 claims description 35
• 239000012472 biological sample Substances 0.000 claims description 31
• 238000011282 treatment Methods 0.000 claims description 28
• 238000012216 screening Methods 0.000 claims description 27
• 238000004519 manufacturing process Methods 0.000 claims description 23
• 230000002163 immunogen Effects 0.000 claims description 20
• 241001465754 Metazoa Species 0.000 claims description 18
• 231100000419 toxicity Toxicity 0.000 claims description 12
• 230000001988 toxicity Effects 0.000 claims description 12
• 230000003247 decreasing effect Effects 0.000 claims description 11
• 230000008859 change Effects 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 230000009870 specific binding Effects 0.000 claims description 8
• 230000009261 transgenic effect Effects 0.000 claims description 8
• 238000012408 PCR amplification Methods 0.000 claims description 6
• 108060003951 Immunoglobulin Proteins 0.000 claims description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
• 210000004408 hybridoma Anatomy 0.000 claims description 4
• 102000018358 immunoglobulin Human genes 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 3
• 230000003053 immunization Effects 0.000 claims description 3
• 230000002018 overexpression Effects 0.000 claims description 2
• 230000005875 antibody response Effects 0.000 claims 2
• 210000000628 antibody-producing cell Anatomy 0.000 claims 2
• 238000002405 diagnostic procedure Methods 0.000 claims 1
• 102000005962 receptors Human genes 0.000 abstract description 32
• 108020003175 receptors Proteins 0.000 abstract description 32
• 239000013604 expression vector Substances 0.000 abstract description 19
• 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 abstract description 2
• 102000052301 human GNAZ Human genes 0.000 abstract description 2
• 230000001594 aberrant effect Effects 0.000 abstract 1
• 108090000623 proteins and genes Proteins 0.000 description 171
• 102000004169 proteins and genes Human genes 0.000 description 96
• 239000002299 complementary DNA Substances 0.000 description 87
• 235000018102 proteins Nutrition 0.000 description 86
• 108020004414 DNA Proteins 0.000 description 67
• 239000013598 vector Substances 0.000 description 65
• 108091028043 Nucleic acid sequence Proteins 0.000 description 46
• 210000001519 tissue Anatomy 0.000 description 46
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
• 239000013615 primer Substances 0.000 description 40
• 238000004458 analytical method Methods 0.000 description 38
• 238000002869 basic local alignment search tool Methods 0.000 description 36
• 108091034117 Oligonucleotide Proteins 0.000 description 35
• 238000003752 polymerase chain reaction Methods 0.000 description 35
• 208000035475 disorder Diseases 0.000 description 34
• 241000282414 Homo sapiens Species 0.000 description 33
• 235000001014 amino acid Nutrition 0.000 description 31
• 239000013612 plasmid Substances 0.000 description 28
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 27
• 229940024606 amino acid Drugs 0.000 description 27
• 150000001413 amino acids Chemical class 0.000 description 27
• 238000002493 microarray Methods 0.000 description 26
• 238000003556 assay Methods 0.000 description 24
• 238000004422 calculation algorithm Methods 0.000 description 24
• 238000005516 engineering process Methods 0.000 description 22
• 230000002068 genetic effect Effects 0.000 description 21
• 238000000746 purification Methods 0.000 description 21
• 238000012163 sequencing technique Methods 0.000 description 19
• 239000000047 product Substances 0.000 description 18
• 238000006467 substitution reaction Methods 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 17
• 238000013518 transcription Methods 0.000 description 17
• 230000035897 transcription Effects 0.000 description 17
• 108020004635 Complementary DNA Proteins 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• 230000000875 corresponding effect Effects 0.000 description 16
• 108020001507 fusion proteins Proteins 0.000 description 15
• 102000037865 fusion proteins Human genes 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 15
• 238000002360 preparation method Methods 0.000 description 15
• 239000000758 substrate Substances 0.000 description 15
• 230000000692 anti-sense effect Effects 0.000 description 14
• 238000001514 detection method Methods 0.000 description 14
• 230000001105 regulatory effect Effects 0.000 description 14
• 230000003612 virological effect Effects 0.000 description 14
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
• 125000000539 amino acid group Chemical group 0.000 description 13
• 239000003814 drug Substances 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 208000015181 infectious disease Diseases 0.000 description 13
• 238000013519 translation Methods 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 230000001580 bacterial effect Effects 0.000 description 12
• 230000003834 intracellular effect Effects 0.000 description 12
• 239000003446 ligand Substances 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• 241001430294 unidentified retrovirus Species 0.000 description 12
• 102000015636 Oligopeptides Human genes 0.000 description 11
• 108010038807 Oligopeptides Proteins 0.000 description 11
• 239000003550 marker Substances 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 241000700584 Simplexvirus Species 0.000 description 10
• 230000003321 amplification Effects 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 210000000170 cell membrane Anatomy 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 238000001415 gene therapy Methods 0.000 description 10
• 230000001939 inductive effect Effects 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 238000003199 nucleic acid amplification method Methods 0.000 description 10
• 208000030507 AIDS Diseases 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• -1 antibodies Proteins 0.000 description 9
• 201000011510 cancer Diseases 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 210000000349 chromosome Anatomy 0.000 description 9
• 210000004379 membrane Anatomy 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 230000036961 partial effect Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 241000701161 unidentified adenovirus Species 0.000 description 9
• 241000710929 Alphavirus Species 0.000 description 8
• 108700024394 Exon Proteins 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 108091093037 Peptide nucleic acid Proteins 0.000 description 8
• 208000036142 Viral infection Diseases 0.000 description 8
• 230000002759 chromosomal effect Effects 0.000 description 8
• 238000010276 construction Methods 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 206010012601 diabetes mellitus Diseases 0.000 description 8
• 239000005090 green fluorescent protein Substances 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 230000004054 inflammatory process Effects 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 208000030159 metabolic disease Diseases 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 238000012546 transfer Methods 0.000 description 8
• 230000009466 transformation Effects 0.000 description 8
• 241001529453 unidentified herpesvirus Species 0.000 description 8
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 108091006027 G proteins Proteins 0.000 description 7
• 102000030782 GTP binding Human genes 0.000 description 7
• 108091000058 GTP-Binding Proteins 0.000 description 7
• 108010070675 Glutathione transferase Proteins 0.000 description 7
• 102000005720 Glutathione transferase Human genes 0.000 description 7
• 108050002069 Olfactory receptors Proteins 0.000 description 7
• 208000001132 Osteoporosis Diseases 0.000 description 7
• 102000003982 Parathyroid hormone Human genes 0.000 description 7
• 108090000445 Parathyroid hormone Proteins 0.000 description 7
• 108010026552 Proteome Proteins 0.000 description 7
• 108091034057 RNA (poly(A)) Proteins 0.000 description 7
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 230000007812 deficiency Effects 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 230000002526 effect on cardiovascular system Effects 0.000 description 7
• 239000003623 enhancer Substances 0.000 description 7
• 230000002496 gastric effect Effects 0.000 description 7
• 239000011521 glass Substances 0.000 description 7
• 230000028993 immune response Effects 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 238000013507 mapping Methods 0.000 description 7
• 229960001319 parathyroid hormone Drugs 0.000 description 7
• 239000000199 parathyroid hormone Substances 0.000 description 7
• 239000002987 primer (paints) Substances 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 231100000167 toxic agent Toxicity 0.000 description 7
• 239000003440 toxic substance Substances 0.000 description 7
• 201000001320 Atherosclerosis Diseases 0.000 description 6
• 241000196324 Embryophyta Species 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 102000012547 Olfactory receptors Human genes 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 210000001124 body fluid Anatomy 0.000 description 6
• 210000001072 colon Anatomy 0.000 description 6
• 201000006549 dyspepsia Diseases 0.000 description 6
• 230000002255 enzymatic effect Effects 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 238000003018 immunoassay Methods 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 230000000926 neurological effect Effects 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 230000009385 viral infection Effects 0.000 description 6
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 208000024172 Cardiovascular disease Diseases 0.000 description 5
• 108091035707 Consensus sequence Proteins 0.000 description 5
• 238000001712 DNA sequencing Methods 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 208000008589 Obesity Diseases 0.000 description 5
• 108090000820 Rhodopsin Proteins 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 239000012153 distilled water Substances 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 235000020824 obesity Nutrition 0.000 description 5
• 238000004806 packaging method and process Methods 0.000 description 5
• 210000000496 pancreas Anatomy 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 4
• 206010002383 Angina Pectoris Diseases 0.000 description 4
• 208000019901 Anxiety disease Diseases 0.000 description 4
• 102100036465 Autoimmune regulator Human genes 0.000 description 4
• 102000009410 Chemokine receptor Human genes 0.000 description 4
• 108050000299 Chemokine receptor Proteins 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 239000003155 DNA primer Substances 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108091060211 Expressed sequence tag Proteins 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 201000011240 Frontotemporal dementia Diseases 0.000 description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
• 101710154606 Hemagglutinin Proteins 0.000 description 4
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 4
• 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 4
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 4
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 4
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
• 206010033645 Pancreatitis Diseases 0.000 description 4
• ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
• 101710176177 Protein A56 Proteins 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 102100040756 Rhodopsin Human genes 0.000 description 4
• 241000714474 Rous sarcoma virus Species 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 238000000137 annealing Methods 0.000 description 4
• 230000036506 anxiety Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 4
• 230000003115 biocidal effect Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 201000001352 cholecystitis Diseases 0.000 description 4
• 230000007882 cirrhosis Effects 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 201000001981 dermatomyositis Diseases 0.000 description 4
• 206010014665 endocarditis Diseases 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 239000000185 hemagglutinin Substances 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 231100000283 hepatitis Toxicity 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 210000000688 human artificial chromosome Anatomy 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000002551 irritable bowel syndrome Diseases 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 229920002521 macromolecule Polymers 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 206010028417 myasthenia gravis Diseases 0.000 description 4
• 210000000653 nervous system Anatomy 0.000 description 4
• 239000002858 neurotransmitter agent Substances 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 208000005987 polymyositis Diseases 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000002685 pulmonary effect Effects 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 201000000980 schizophrenia Diseases 0.000 description 4
• 208000012672 seasonal affective disease Diseases 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 201000005060 thrombophlebitis Diseases 0.000 description 4
• 238000010361 transduction Methods 0.000 description 4
• 230000026683 transduction Effects 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 241000972773 Aulopiformes Species 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 108010042407 Endonucleases Proteins 0.000 description 3
• 241001635598 Enicostema Species 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
• 108091092195 Intron Proteins 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
• 102000001796 Melanocortin 4 receptors Human genes 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 102000016978 Orphan receptors Human genes 0.000 description 3
• 108070000031 Orphan receptors Proteins 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
• 102100037505 Secretin Human genes 0.000 description 3
• 108010086019 Secretin Proteins 0.000 description 3
• 241000710961 Semliki Forest virus Species 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010006785 Taq Polymerase Proteins 0.000 description 3
• 102100036407 Thioredoxin Human genes 0.000 description 3
• 241000723873 Tobacco mosaic virus Species 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 3
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
• 102000004136 Vasopressin Receptors Human genes 0.000 description 3
• 108090000643 Vasopressin Receptors Proteins 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
• 229960004373 acetylcholine Drugs 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000011543 agarose gel Substances 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 208000003455 anaphylaxis Diseases 0.000 description 3
• 238000003491 array Methods 0.000 description 3
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 210000002459 blastocyst Anatomy 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 208000015114 central nervous system disease Diseases 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• 229940095074 cyclic amp Drugs 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 208000010643 digestive system disease Diseases 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 238000007877 drug screening Methods 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 229940049906 glutamate Drugs 0.000 description 3
• 229930195712 glutamate Natural products 0.000 description 3
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
• 229940027941 immunoglobulin g Drugs 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000003068 molecular probe Substances 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 239000000813 peptide hormone Substances 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 235000019515 salmon Nutrition 0.000 description 3
• 229960002101 secretin Drugs 0.000 description 3
• OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 229940076279 serotonin Drugs 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 108060008226 thioredoxin Proteins 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 210000001541 thymus gland Anatomy 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000008791 toxic response Effects 0.000 description 3
• 230000002110 toxicologic effect Effects 0.000 description 3
• 231100000027 toxicology Toxicity 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• 208000003200 Adenoma Diseases 0.000 description 2
• 102000055025 Adenosine deaminases Human genes 0.000 description 2
• 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 description 2
• 102000017910 Adrenergic receptor Human genes 0.000 description 2
• 208000007887 Alphavirus Infections Diseases 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 208000031091 Amnestic disease Diseases 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000003017 Aortic Valve Stenosis Diseases 0.000 description 2
• 241000712891 Arenavirus Species 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 206010003226 Arteriovenous fistula Diseases 0.000 description 2
• 208000004300 Atrophic Gastritis Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 208000012219 Autonomic Nervous System disease Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 206010004552 Bicuspid aortic valve Diseases 0.000 description 2
• 208000015163 Biliary Tract disease Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000004020 Brain Abscess Diseases 0.000 description 2
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• 241000244202 Caenorhabditis Species 0.000 description 2
• 208000004434 Calcinosis Diseases 0.000 description 2
• 102000055006 Calcitonin Human genes 0.000 description 2
• 108060001064 Calcitonin Proteins 0.000 description 2
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 108090000565 Capsid Proteins Proteins 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102100023321 Ceruloplasmin Human genes 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
• 206010008635 Cholestasis Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 206010010099 Combined immunodeficiency Diseases 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 108020004394 Complementary RNA Proteins 0.000 description 2
• 208000002330 Congenital Heart Defects Diseases 0.000 description 2
• 206010010774 Constipation Diseases 0.000 description 2
• 241000711573 Coronaviridae Species 0.000 description 2
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
• 208000019736 Cranial nerve disease Diseases 0.000 description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 108010017826 DNA Polymerase I Proteins 0.000 description 2
• 102000004594 DNA Polymerase I Human genes 0.000 description 2
• 208000019505 Deglutition disease Diseases 0.000 description 2
• 206010012289 Dementia Diseases 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 208000012239 Developmental disease Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 2
• 206010013883 Dwarfism Diseases 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 206010062608 Endocarditis noninfective Diseases 0.000 description 2
• 102000004533 Endonucleases Human genes 0.000 description 2
• 241000701867 Enterobacteria phage T7 Species 0.000 description 2
• 206010058838 Enterocolitis infectious Diseases 0.000 description 2
• 206010014950 Eosinophilia Diseases 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 206010015251 Erythroblastosis foetalis Diseases 0.000 description 2
• 208000007217 Esophageal Stenosis Diseases 0.000 description 2
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 206010061846 Extradural abscess Diseases 0.000 description 2
• 241000711950 Filoviridae Species 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 101800002068 Galanin Proteins 0.000 description 2
• 102000011392 Galanin receptor Human genes 0.000 description 2
• 108050001605 Galanin receptor Proteins 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 208000036495 Gastritis atrophic Diseases 0.000 description 2
• 208000005577 Gastroenteritis Diseases 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 2
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 102000051325 Glucagon Human genes 0.000 description 2
• 108060003199 Glucagon Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 206010061201 Helminthic infection Diseases 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• 206010019708 Hepatic steatosis Diseases 0.000 description 2
• 206010019713 Hepatic vein thrombosis Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 2
• 206010021518 Impaired gastric emptying Diseases 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 102100034349 Integrase Human genes 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 206010023126 Jaundice Diseases 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 206010062062 Large intestinal obstruction Diseases 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 208000024369 Libman-Sacks endocarditis Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 206010025327 Lymphopenia Diseases 0.000 description 2
• 206010026712 Mallory-Weiss syndrome Diseases 0.000 description 2
• 206010027202 Meningitis bacterial Diseases 0.000 description 2
• 206010027260 Meningitis viral Diseases 0.000 description 2
• 208000036626 Mental retardation Diseases 0.000 description 2
• 206010068836 Metabolic myopathy Diseases 0.000 description 2
• 208000003430 Mitral Valve Prolapse Diseases 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 208000003926 Myelitis Diseases 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• 206010028643 Myopathy endocrine Diseases 0.000 description 2
• 208000023137 Myotoxicity Diseases 0.000 description 2
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 206010030184 Oesophageal spasm Diseases 0.000 description 2
• 206010030194 Oesophageal stenosis Diseases 0.000 description 2
• 241000713112 Orthobunyavirus Species 0.000 description 2
• 208000027099 Paranoid disease Diseases 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 201000004602 Peliosis Hepatis Diseases 0.000 description 2
• 208000008469 Peptic Ulcer Diseases 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 108010002724 Pheromone Receptors Proteins 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 241000709664 Picornaviridae Species 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 206010058989 Portal vein occlusion Diseases 0.000 description 2
• 201000009454 Portal vein thrombosis Diseases 0.000 description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
• 102000029797 Prion Human genes 0.000 description 2
• 108091000054 Prion Proteins 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• 206010036774 Proctitis Diseases 0.000 description 2
• 206010036783 Proctitis ulcerative Diseases 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 206010037075 Protozoal infections Diseases 0.000 description 2
• 108020004518 RNA Probes Proteins 0.000 description 2
• 239000003391 RNA probe Substances 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 208000003782 Raynaud disease Diseases 0.000 description 2
• 208000012322 Raynaud phenomenon Diseases 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 241000702263 Reovirus sp. Species 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 201000007981 Reye syndrome Diseases 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 102100028927 Secretin receptor Human genes 0.000 description 2
• 206010049416 Short-bowel syndrome Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• 241000710960 Sindbis virus Species 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• 102100022831 Somatoliberin Human genes 0.000 description 2
• 101710142969 Somatoliberin Proteins 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 2
• 201000000002 Subdural Empyema Diseases 0.000 description 2
• 108091027544 Subgenomic mRNA Proteins 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
• 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
• 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
• 208000000323 Tourette Syndrome Diseases 0.000 description 2
• 208000016620 Tourette disease Diseases 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• 206010046996 Varicose vein Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
• GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
• 108010004977 Vasopressins Proteins 0.000 description 2
• 102000002852 Vasopressins Human genes 0.000 description 2
• 208000012346 Venoocclusive disease Diseases 0.000 description 2
• 206010047249 Venous thrombosis Diseases 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 201000011032 Werner Syndrome Diseases 0.000 description 2
• 208000027207 Whipple disease Diseases 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• 208000009621 actinic keratosis Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 230000006986 amnesia Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 206010002906 aortic stenosis Diseases 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 201000009904 bacterial meningitis Diseases 0.000 description 2
• 208000018300 basal ganglia disease Diseases 0.000 description 2
• 208000021654 bicuspid aortic valve disease Diseases 0.000 description 2
• 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000008236 biological pathway Effects 0.000 description 2
• 210000000625 blastula Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 230000002308 calcification Effects 0.000 description 2
• 229960004015 calcitonin Drugs 0.000 description 2
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 208000005761 carcinoid heart disease Diseases 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 206010007776 catatonia Diseases 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 206010008129 cerebral palsy Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 239000013522 chelant Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 201000001883 cholelithiasis Diseases 0.000 description 2
• 230000007870 cholestasis Effects 0.000 description 2
• 231100000359 cholestasis Toxicity 0.000 description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 208000028831 congenital heart disease Diseases 0.000 description 2
• 230000006552 constitutive activation Effects 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 208000016097 disease of metabolism Diseases 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• 208000002296 eclampsia Diseases 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000000295 emission spectrum Methods 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 230000002616 endonucleolytic effect Effects 0.000 description 2
• 208000037902 enteropathy Diseases 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 201000000165 epidural abscess Diseases 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 230000001667 episodic effect Effects 0.000 description 2
• 201000005619 esophageal carcinoma Diseases 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 201000006061 fatal familial insomnia Diseases 0.000 description 2
• 208000001031 fetal erythroblastosis Diseases 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
• 229940028334 follicle stimulating hormone Drugs 0.000 description 2
• 210000000232 gallbladder Anatomy 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 210000000609 ganglia Anatomy 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 208000010749 gastric carcinoma Diseases 0.000 description 2
• 208000018685 gastrointestinal system disease Diseases 0.000 description 2
• 208000001288 gastroparesis Diseases 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 102000054767 gene variant Human genes 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 210000004392 genitalia Anatomy 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
• 229960004666 glucagon Drugs 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 208000018578 heart valve disease Diseases 0.000 description 2
• 208000024798 heartburn Diseases 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 208000007386 hepatic encephalopathy Diseases 0.000 description 2
• 206010019680 hepatic infarction Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 201000011200 hepatorenal syndrome Diseases 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 108091008039 hormone receptors Proteins 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 208000036796 hyperbilirubinemia Diseases 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 208000015210 hypertensive heart disease Diseases 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000027139 infectious colitis Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 201000007119 infective endocarditis Diseases 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 208000028774 intestinal disease Diseases 0.000 description 2
• 208000003243 intestinal obstruction Diseases 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 206010023497 kuru Diseases 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 230000029226 lipidation Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 231100001023 lymphopenia Toxicity 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 239000006249 magnetic particle Substances 0.000 description 2
• 201000007261 marantic endocarditis Diseases 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000000329 molecular dynamics simulation Methods 0.000 description 2
• 230000036651 mood Effects 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 230000002988 nephrogenic effect Effects 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 208000018360 neuromuscular disease Diseases 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 208000016135 nonbacterial thrombotic endocarditis Diseases 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000003071 parasitic effect Effects 0.000 description 2
• 230000000849 parathyroid Effects 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 210000003899 penis Anatomy 0.000 description 2
• 208000000689 peptic esophagitis Diseases 0.000 description 2
• 208000011906 peptic ulcer disease Diseases 0.000 description 2
• 208000008494 pericarditis Diseases 0.000 description 2
• 208000029308 periodic paralysis Diseases 0.000 description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 239000002427 pheromone receptor Substances 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 201000011461 pre-eclampsia Diseases 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
• 238000007639 printing Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000004952 protein activity Effects 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 208000024981 pyrosis Diseases 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 206010061928 radiculitis Diseases 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 208000004124 rheumatic heart disease Diseases 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 210000003079 salivary gland Anatomy 0.000 description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 description 2
• 108700027603 secretin receptor Proteins 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 201000000498 stomach carcinoma Diseases 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 208000001608 teratocarcinoma Diseases 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 230000002537 thrombolytic effect Effects 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002463 transducing effect Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 230000010415 tropism Effects 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 208000027185 varicose disease Diseases 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 201000011531 vascular cancer Diseases 0.000 description 2
• 206010055031 vascular neoplasm Diseases 0.000 description 2
• 229960003726 vasopressin Drugs 0.000 description 2
• 201000010044 viral meningitis Diseases 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 238000001086 yeast two-hybrid system Methods 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
• PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
• OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
• 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
• 241000173351 Camvirus Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 239000005496 Chlorsulfuron Substances 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 206010008674 Cholinergic syndrome Diseases 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 241000192700 Cyanobacteria Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 241000168726 Dictyostelium discoideum Species 0.000 description 1
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 201000003542 Factor VIII deficiency Diseases 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229940125633 GPCR agonist Drugs 0.000 description 1
• 108091008885 GPCRs class E Proteins 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• SAEBUDRWKUXLOM-ACZMJKKPSA-N Glu-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O SAEBUDRWKUXLOM-ACZMJKKPSA-N 0.000 description 1
• QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
• CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
• 206010072079 Glucocorticoid deficiency Diseases 0.000 description 1
• 102000053187 Glucuronidase Human genes 0.000 description 1
• 108010060309 Glucuronidase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• WZOGEMJIZBNFBK-CIUDSAMLSA-N His-Asp-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O WZOGEMJIZBNFBK-CIUDSAMLSA-N 0.000 description 1
• SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
• YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
• 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
• 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
• 201000002980 Hyperparathyroidism Diseases 0.000 description 1
• 101150027427 ICP4 gene Proteins 0.000 description 1
• USXAYNCLFSUSBA-MGHWNKPDSA-N Ile-Phe-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N USXAYNCLFSUSBA-MGHWNKPDSA-N 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108700005090 Lethal Genes Proteins 0.000 description 1
• PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• 108010062166 Lys-Asn-Asp Proteins 0.000 description 1
• BYPMOIFBQPEWOH-CIUDSAMLSA-N Lys-Asn-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BYPMOIFBQPEWOH-CIUDSAMLSA-N 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 108010008364 Melanocortins Proteins 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 101100333728 Mus musculus Ercc8 gene Proteins 0.000 description 1
• 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• 108091093105 Nuclear DNA Proteins 0.000 description 1
• 108091005461 Nucleic proteins Chemical group 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108010093625 Opioid Peptides Proteins 0.000 description 1
• 102000001490 Opioid Peptides Human genes 0.000 description 1
• 102000010175 Opsin Human genes 0.000 description 1
• 108050001704 Opsin Proteins 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
• 101800000989 Oxytocin Proteins 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
• 241001483952 Peach chlorotic mottle virus Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 108010003541 Platelet Activating Factor Proteins 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 101710097451 Putative G-protein coupled receptor Proteins 0.000 description 1
• 102100039117 Putative vomeronasal receptor-like protein 4 Human genes 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
• 101150006985 STE2 gene Proteins 0.000 description 1
• 101100204213 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STE3 gene Proteins 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
• CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• 102000003141 Tachykinin Human genes 0.000 description 1
• 101000783611 Takifugu rubripes 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102100029337 Thyrotropin receptor Human genes 0.000 description 1
• 108700009124 Transcription Initiation Site Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• SWSUXOKZKQRADK-FDARSICLSA-N Trp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SWSUXOKZKQRADK-FDARSICLSA-N 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
• KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
• AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
• GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
• LZRWTJSPTJSWDN-FKBYEOEOSA-N Val-Trp-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LZRWTJSPTJSWDN-FKBYEOEOSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• 108700029631 X-Linked Genes Proteins 0.000 description 1
• 208000028247 X-linked inheritance Diseases 0.000 description 1
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 108010047495 alanylglycine Proteins 0.000 description 1
• 108010070944 alanylhistidine Proteins 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000004410 anthocyanin Substances 0.000 description 1
• 229930002877 anthocyanin Natural products 0.000 description 1
• 235000010208 anthocyanin Nutrition 0.000 description 1
• 150000004636 anthocyanins Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000006583 body weight regulation Effects 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 229950004398 broxuridine Drugs 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000004094 calcium homeostasis Effects 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 239000005081 chemiluminescent agent Substances 0.000 description 1
• 108091008690 chemoreceptors Proteins 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 238000009402 cross-breeding Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000005183 environmental health Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000009969 flowable effect Effects 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000008570 general process Effects 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 230000001456 gonadotroph Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• 108091005708 gustatory receptors Proteins 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000009429 hemophilia B Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 239000000938 histamine H1 antagonist Substances 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 229940098197 human immunoglobulin g Drugs 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 238000007641 inkjet printing Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 244000000056 intracellular parasite Species 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000007852 inverse PCR Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 101710130522 mRNA export factor Proteins 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 239000002865 melanocortin Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 201000003152 motion sickness Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 239000000472 muscarinic agonist Substances 0.000 description 1
• 230000003551 muscarinic effect Effects 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 210000001706 olfactory mucosa Anatomy 0.000 description 1
• 210000001517 olfactory receptor neuron Anatomy 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 239000003399 opiate peptide Substances 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
• 229960001723 oxytocin Drugs 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 108010011903 peptide receptors Proteins 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 238000000206 photolithography Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 208000006155 precocious puberty Diseases 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000001915 proofreading effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000018883 protein targeting Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 244000000040 protozoan parasite Species 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 125000006853 reporter group Chemical group 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000005204 segregation Methods 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 210000000697 sensory organ Anatomy 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000001548 stomatognathic system Anatomy 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 108060008037 tachykinin Proteins 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 108091008023 transcriptional regulators Proteins 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
• QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1